Knowledge Ecology International

28 Organizations Ask President Obama to Support Colombian Compulsory License on Expensive Leukemia Drug

Posted on May 28, 2016 by Zack Struver

Contact:
(U.S.) Andrew Goldman, KEI: andrew.goldman@keionline.org or +1 (202) 332-2670
(Colombia) Andrea Carolina Reyes Rojas, Misión Salud: subdireccion@mision-salud.org
(Colombia) Dr. Francisco Rossi, IFARMA: francisco_rossi@hotmail.com
(More on Colombia here: /colombia)

Washington, DC — Today, 28 organizations that support the advancement of public health, as well as the successful continuation of the peace process in Colombia, urged President Obama to voice U.S. support for Colombia’s right to grant a compulsory license on an expensive leukemia drug. Continue Reading →

HAI/KEI intervention at the WHA69 on the negotiations on an R&D agreement

Posted on May 27, 2016 by KEI Staff

The following is the intervention on behalf of Stichting Health Action International (HAI) at 69th World Health Assembly, Agenda Item 16.2: Follow-up to the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination – Report of the open-ended meeting of Member States.

KEI worked with HAI on the statement, and it was delivered by James Love

Continue Reading →

Sens. Sherrod Brown and Bernie Sanders send letter to USTR condemning pressure on Colombia compulsory license for cancer drug

Posted on May 27, 2016 by Andrew Goldman

(More on Colombia here: /colombia)

In response to reports of USTR pressure on Colombia’s potential compulsory license for imatinib, Senators Sherrod Brown, D-Ohio, and Bernie Sanders, I-Vt., have sent a letter to USTR objecting “to any efforts to protect the public health of Colombians in a way that is appropriate, effective, and consistent with the country’s trade and public health obligations,” and condemning as unconscionable “that any representatives of the U.S. government would threaten to rescind funding for Colombia’s peace iniative if a compulsory license for Glivec were issued.” Continue Reading →

15 House Dems Press USTR to Clarify Position on Compulsory Licensing of cancer drug patent in Colombia

Posted on May 26, 2016 by Andrew Goldman

Yesterday, fifteen House Democrats sent a letter to Ambassador Michael Froman at the United States Trade Representative to express serious concern that the United States officials have been pressuring Colombia to abandon the process of issuing a compulsory license on imatinib. The letter can be read here.

Continue Reading →

Senator Hatch Defends Pressure on Colombia in Interview Regarding Imatinib

Posted on May 25, 2016 by Andrew Goldman

Yesterday, Colombia’s W Radio aired an interview with Senator Orrin Hatch, R-Utah, where he was asked about the reports of pressure on Colombia from the Senate Finance Committee, which he chairs, with regard to the compulsory license process for the expensive leukemia drug, imatinib.

Continue Reading →

WHA 69: Colombian Minister of Health Calls on WHO to Support the Regulation of Drug Monopolies

Posted on May 25, 2016 by Andrew Goldman

(More on Colombia here: /colombia)

On May 24, 2016, Colombia’s Minister of Health, Alejandro Gaviria, made an intervention at the World Health Assembly that referred to the pressure Colombia has been facing with regard to the potential compulsory license for imatinib and called for the WHO to support members to ensure sustainable development through the regulation of pharmaceutical monopolies and promoting competition, transparency, and the rational use of drugs.
Continue Reading →

WHO at the crossroads: negotiations to fund global R&D mired in eight pages of [bracketed] text

Posted on May 21, 2016 by Thiru

On Friday, 20 May 2016, the World Health Organization (WHO) published document A69/40, Follow-up to the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination — Report of the open-ended meeting of Member States. This… Continue Reading →

Background FAQ on Glivec (imatinib) compulsory license in Colombia

Posted on May 19, 2016 by Andrew Goldman

(More on Colombia here: /colombia) For more information, contact: (U.S.) Andrew Goldman, KEI: andrew.goldman@keionline.org or +1 (202) 332-2670 (Colombia) Andrea Carolina Reyes Rojas, Misión Salud: subdireccion@mision-salud.org (Colombia) Dr. Francisco Rossi, IFARMA: francisco_rossi@hotmail.com Frequently Asked Questions What is happening in Colombia… Continue Reading →

Letter from KEI, Public Citizen, Oxfam America and Health GAP to Senator Hatch, regarding Colombia Compulsory License

Posted on May 19, 2016 by James Love

Attached is a letter that KEI, Public Citizen, Oxfam America and Health GAP have sent to Senator Hatch, via the Senate Finance Committee, objecting to the pressure his office has put on Colombia over a compulsory license on patents held by Novartis for the cancer drug Gleevec. This refers to the accounts of pressure from Hatch’s office that are described in two letters from the Colombia Embassy in Washington, dated April 27 and April 28, which were recently leaked. Continue Reading →

13 non-profits urge Senate HELP Committee to block floor amendments to 21st Century Cures Act counterpart

Posted on May 19, 2016 by Zack Struver

Before the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) presents a legislative package of healthcare reforms to the Senate floor for an up-or-down vote, 13 consumer, patient and health non-profit groups sent a letter to HELP Chairman and Ranking Member to ensure that the final legislative package includes only those bills that the HELP Committee reviewed in mark-up sessions.

Continue Reading →

Categories